Orthofix Medical Inc.

OFIX

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000884624

A/B

on the A/B boundary of 369 graded peers in healthcare

rank 70 of 369; percentile 18.8; sampling error 2.5 points; lower is stronger

A B C D E

A/B, the bull



Scoreboard	
Profitability	B percentile 35.1
Solvency	C percentile 48.3
Growth and financing	B percentile 28.9
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $850.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 24, 2026 251 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$9.07 2026-10-30; market equity $369.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

In this Annual Report, the terms "we," "us," "our," "Orthofix," and "the Company" refer to the combined operations of Orthofix Medical Inc. and its consolidated subsidiaries and affiliates, unless the context requires otherwise. Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, Orthofix delivers exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 35.1						
Gross profitability	66.5%	32.4%		13.4	366	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(14.4%)	(6.6%)		31.2	803	2025-12-31
Gross margin stability, five years	3.6 pts	2.8 pts		60.6	242	2025-12-31
Solvency, sleeve percentile 48.3						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	1.02	(0.35)		32.7	748	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2014-12-31; latest annual assets end 2025-12-31						
Current ratio	2.45x	2.92x		64.0	829	2025-12-31
Growth and financing, sleeve percentile 28.9						
Revenue growth, three-year compound	21.3%	10.1%		30.7	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	22.9%	2.2%		19.3	696	2025-12-31
Net share issuance, one year	2.9%	2.5%		36.7	631	2026-02-20

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
65	InnovAge Holding Corp. (INNV)	17.4	A	fortress balance sheet
66	Aurinia Pharmaceuticals Inc. (AUPH)	17.7	A/B	
67	Definium Therapeutics, Inc. (DFTX)	17.9	A/B	dilution
68	UFP Technologies Inc. (UFPT)	18.2	A/B	
69	Conmed Corp. (CNMD)	18.5	A/B	
70	Orthofix Medical Inc. (OFIX)	18.8	A/B	
71	Dexcom Inc. (DXCM)	19.0	A/B	fortress balance sheet
72	Adma Biologics, Inc. (ADMA)	19.3	A/B	late filer, fortress balance sheet
73	Merit Medical Systems Inc. (MMSI)	19.6	A/B	
74	Ocular Therapeutix, Inc. (OCUL)	19.8	A/B	dilution
75	Zoetis Inc. (ZTS)	20.1	A/B	

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(39.1%)	(2.2%)	24
Distance from 52-week high	(44.0%)	(28.7%)	33
EBIT to enterprise value	(19.3%)	(1.4%)	24

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	(0.3%)	(1.0%)	52
Book value to price	1.16	0.28	88
Sales to price	2.23	0.30	92
Composite equity issuance, five years	73.6%	20.5%	71
Relative strength against the sector, log excess return	(0.66)	(0.19)	24

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$103.8M
Operating cash flow, four quarters	$16.3M
Months of runway	not finite
Days since last periodic filing	89 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$3.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$566.0M	2025-12-31	2026-02-24	10-K	26-065189
2	assets	us-gaap:Assets	$850.6M	2025-12-31	2026-02-24	10-K	26-065189
3	operating income	us-gaap:OperatingIncomeLoss	-$84.6M	2024-12-31	2026-02-24	10-K	26-065189
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$123.9M	2024-12-31	2026-02-24	10-K	26-065189
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.1M	2024-12-31	2026-02-24	10-K	26-065189
6	total debt	us-gaap:LongTermDebt	$157.0M	2024-12-31	2025-02-25	10-K	25-026066
7	book equity	us-gaap:StockholdersEquity	$503.1M	2024-12-31	2026-02-24	10-K	26-065189
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$83.2M	2024-12-31	2026-02-24	10-K	26-065189
9	total debt	us-gaap:LongTermDebt	$94.4M	2023-12-31	2025-02-25	10-K	25-026066
10	book equity	us-gaap:StockholdersEquity	$598.7M	2023-12-31	2026-02-24	10-K	26-065189
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$33.1M	2023-12-31	2026-02-24	10-K	26-065189
12	net income	us-gaap:NetIncomeLoss	-$92.2M	2025-12-31	2026-02-24	10-K	26-065189
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$33.3M	2025-12-31	2026-02-24	10-K	26-065189
14	assets	us-gaap:Assets	$893.3M	2024-12-31	2026-02-24	10-K	26-065189
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$822.3M	2025-12-31	2026-02-24	10-K	26-065189
16	gross profit	us-gaap:GrossProfit	$545.9M	2024-12-31	2026-02-24	10-K	26-065189
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$799.5M	2024-12-31	2026-02-24	10-K	26-065189
18	gross profit	us-gaap:GrossProfit	$486.3M	2023-12-31	2026-02-24	10-K	26-065189
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$746.6M	2023-12-31	2026-02-24	10-K	26-065189
20	gross profit	us-gaap:GrossProfit	$337.2M	2022-12-31	2025-02-25	10-K	25-026066
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$460.7M	2022-12-31	2025-02-25	10-K	25-026066
22	gross profit	us-gaap:GrossProfit	$349.6M	2021-12-31	2024-03-05	10-K	24-025877
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$464.5M	2021-12-31	2024-03-05	10-K	24-025877
24	current assets	us-gaap:AssetsCurrent	$416.8M	2025-12-31	2026-02-24	10-K	26-065189
25	current liabilities	us-gaap:LiabilitiesCurrent	$170.5M	2025-12-31	2026-02-24	10-K	26-065189

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$368.3M	2025-12-31	2026-02-24	10-K	26-065189
27	operating income	us-gaap:OperatingIncomeLoss	-$81.4M	2025-12-31	2026-02-24	10-K	26-065189
28	book equity	us-gaap:StockholdersEquity	$450.0M	2025-12-31	2026-02-24	10-K	26-065189
29	liabilities	us-gaap:Liabilities	$400.6M	2025-12-31	2026-02-24	10-K	26-065189
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$60.1M	2024-12-31	2026-02-24	10-K	26-065189
31	operating income	us-gaap:OperatingIncomeLoss	$17.1M	2014-12-31	2017-02-27	10-K	17-002569
32	interest expense	us-gaap:InterestExpense	$1.8M	2014-12-31	2015-04-29	10-K	15-003012
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$34.6M	2025-12-31	2026-02-24	10-K	26-065189
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$25.8M	2024-12-31	2026-02-24	10-K	26-065189
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$34.9M	2024-12-31	2026-02-24	10-K	26-065189
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$45.8M	2023-12-31	2026-02-24	10-K	26-065189
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$60.3M	2023-12-31	2024-03-05	10-K	24-025877
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$11.5M	2022-12-31	2025-02-25	10-K	25-026066
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21.4M	2022-12-31	2024-03-05	10-K	24-025877
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$77.3M	2025-12-31	2026-02-24	10-K	26-065189
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$90.8M	2025-12-31	2026-02-24	10-K	26-065189
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.4M	2025-12-31	2026-02-24	10-K	26-065189
43	current assets	us-gaap:AssetsCurrent	$433.3M	2024-12-31	2026-02-24	10-K	26-065189
44	current liabilities	us-gaap:LiabilitiesCurrent	$168.6M	2024-12-31	2026-02-24	10-K	26-065189
45	assets	us-gaap:Assets	$925.3M	2023-12-31	2025-02-25	10-K	25-026066
46	assets	us-gaap:Assets	$458.6M	2022-12-31	2024-03-05	10-K	24-025877
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,144,397	2026-02-20	2026-02-24	10-K	26-065189
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	39,022,492	2025-02-21	2025-02-25	10-K	25-026066

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.